Details of the Drug Reposition

General Information of This Drug (ID: DMUMCB9)

Drug Name
Amelubant   DMUMCB9
Synonyms
Amelubant [INN]; BIIL 283 BS; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pulmonary disease DIS6060I 1B10-1F85 Phase 2 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cystic fibrosis DIS2OK1Q CA25 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02249338) Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD) in Boehringer Ingelheim.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8463).